

Webinars

for patients

Sickle Cell Disease

Topic on Focus

EuroBloodNet 

Sickle cell disease and autoimmune diseases

Slimane Allali

Department of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants malades Hospital
Assistance Publique – Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France
Laboratory of molecular mechanisms of hematologic disorders and therapeutic implications
IMAGINE Institute – INSERM U1163, Paris, France


ERN-EuroBloodNet subnetwork: Red Blood Cell

Paris– France

04 July 2022




Co-funded by
the Health Programme
of the European Union




Conflicts of interest

I have no conflict of interest to declare.




Webinar rules

- **30 min presentation + 15 min Q&A session**
- **Microphones will be muted by host to avoid back noise**
- **Please, stop your video to improve internet connexion**
- **Send your questions during the presentation through the chat**




Learning objectives

- 1. How could sickle cell disease (SCD) promote autoimmunity?**
- 2. Are patients with SCD more prone to autoimmune diseases?**
- 3. What are the therapeutic implications of autoimmunity in SCD?**



Learning objectives


- 1. How could sickle cell disease (SCD) promote autoimmunity?**
2. Are patients with SCD more prone to autoimmune diseases?
3. What are the therapeutic implications of autoimmunity in SCD?



Autoimmunity


“Autoimmunity is defined as an immune response leading to reaction with self antigen, i.e. any molecule that is a normal body constituent”.


Delves, Encyclopedia of Immunology 1998



Autoimmune diseases

- Autoimmune diseases occur when immunity **fails to control autoreactive lymphocytes** that become responsible for **damages of tissues** containing the autoantigens.
- Breaking of peripheral tolerance may be caused by:
 - **Molecular mimicry** (infectious agents...)
 - **Inflammation**
 - Abnormal **leukocytes**, **cytokines** or **complement**
 - Sustained production of **type I interferon**
- Specific genotypes (HLA in particular) may predispose to autoimmune diseases.
- Main triggers of autoimmune diseases are **infections**.







Classical pathophysiology



Innate immune cells in SCD







How could SCD promote autoimmunity?

- All innate immune cells are **increased** (absolute count) in SCD.
- **Chronic hemolysis** activates innate immune cells in SCD.

Allali, Haematologica 2020




Belcher, Blood 2014




How could SCD promote autoimmunity?

- The **complement** pathway is **hyperactivated in SCD** patients, even in the **steady state**.



Roumenina, Am J Hematol 2020







How could SCD promote autoimmunity?


- **Interferon alpha** plasma level is increased in SCD patients with **positive correlation with heme** level.
- **Type I IFN inducible genes** are **upregulated in monocytes** from SCD patients.






- A **monocyte transcriptome** involving **interferon signaling** discriminates **SCD** from other **hemolytic anemias**.






Learning objectives

1. How could SCD promote autoimmunity?
- 2. Are patients with SCD more prone to autoimmune diseases?**
3. What are the therapeutic implications of autoimmunity in SCD?




Autoimmune diseases




Wang, *J Intern Med* 2021

SCD



Adapted from Thein, *Blood* 2018




Autoimmune diseases

Disease	Age at onset (years)	Gender (female/male)	Monozygotic twin concordance ^a	Incidence (per 100 000 person-years)			References
				Europe	North America	Asia and Middle East	
Multiple sclerosis	20–40	2/1	9–31%	0.8–8.7	2.7–7.5	0.7–3.6	[12, 145]
Type 1 diabetes	6–13	1/1	13–48%	>20	10–20	<1	[146, 147]
Primary biliary cirrhosis	50–60	10/1	63%	1.4–3.1	2.7 (USA)	0.34–0.42	[148–151]
Autoimmune hepatitis	<40 (T1) 2–14 (T2)	4/1 (T1) 10/1 (T2)	Only case reports	1.07–3.0	0.5 (USA)	0.08–0.15 (Japan)	[152–154]
Graves' disease	50–60	5/1	17–60%	21–50	38	120	[155, 156]
Crohn's disease	15–30, 60–80	1/1.2	4%	3.1–12.7	6.9–20.2	0.24–1.34	[157–159]
Ulcerative colitis	15–30, 60–80	1/1	6.3–18.8%	4.1–16.5	8.3–19.2	0.36–6.02	[159, 160]
Coeliac disease	Childhood	1/1	75–83%	1.5–8.7 (all ages)	0.9–9.1 (all ages)	Unclear	[161, 162]
Addison's disease	15–45	0.8–2.4/1	Discordant pair	0.56–6.20	1 (USA)	Unclear	[163, 164]
Sjogren's syndrome	40–50	9/1	Only case reports	5.3 (north-west Greece)	3–5 (USA)	6.57	[165–167]
Systemic lupus erythematosus	30–50	9/1	11–25%	1.0–5.0	1.2–8.7	0.9–3.1	[168–170]
Rheumatoid arthritis	44–55	2/1	15–30%	9–36	31–45	8–42	[171–173]


Organ specific


Systemic diseases



Systemic lupus erythematosus (SLE)


- SLE is a **frequent** autoimmune disease affecting **several organs**, including the joints, skin, brain, lungs, kidneys, blood vessels...
- SLE can affect people of **all age**, with a greater risk in **women** of childbearing age.
- The **symptoms are varied** and include: fatigue, fever, pain/swelling in the joints, skin rashes, photosensitivity, oral ulcers, pleural and heart effusions,...
- **Early diagnosis** and treatment initiation help reduce the damaging effects of SLE and improve quality of life.






Rheumatoid arthritis (RA)

- RA is a **very frequent** autoimmune disease that primarily affects **the joints** but may also affect the skin, eyes, lungs, heart, nerves...
- RA affects people of **40-60 yrs**, with a greater risk in **women**.
- The most frequent **symptoms** include: **pain/swelling/stiffness/deformation of the joints**, rheumatoid nodules, (epi)scleritis, interstitial lung disease, fatigue,...
- **Anti-inflammatory treatments** (Methotrexate,...) improve symptoms and slow disease progression when started early.





Autoimmune diseases and SCD

- Main autoimmune diseases reported in SCD:
 - **Systemic lupus erythematosus (SLD)**
 - **Rheumatoid arthritis (RA)**

Piccin, Br J Haematol 2022

- **Overlapping symptoms** → diagnosis may be **difficult**.

Pain (joints, musculature), fever, elevated inflammatory markers...

- **Specific symptoms** of autoimmune diseases should be sought...


Malar rash, alopecia, photosensitivity, oral ulcers, pericarditis, pleuritis...



Sibanda, BMJ Glob Health 2018

- ... to avoid **diagnostic delays**

Li-Thiao-Te, Pediatr Rheumatol Online J 2018



Systemic lupus erythematosus (SLE) and SCD

- **1/1000** in the **general population** / unknown but possibly **increased prevalence in SCD (3-14/1000)**

Saxena, J Pediatr Hematol Oncol 2003

Li-Thiao-Te, Pediatr Rheumatol Online J 2018

- 2019 EULAR revised SLE diagnostic criteria **cannot be used for SCD patients.**


Fever, joint involvement, leuko/thrombocytopenia...: very frequent in SCD

Piccin, Br J Haematol 2022



- **Anti-ds-DNA** and **anti-Sm** antibodies have **greater specificity than ANA (↑ in 50% of SCD patients).**

Toli-Ndour J Rheumatol 2011



Rheumatoid arthritis (RA) and SCD

- **Same incidence (1/100)** as in the general population **but occurs at a younger age**


Mc Farlane, Rheumatology 2017

- Suspected mechanism: **inflammation** and **complement activation** secondary to **synovial ischemia**

Piccin, Br J Haematol 2022

- **Difficult diagnosis** as persistent **joint pain** and biological **inflammation** are frequent in SCD



- **Positive serology** (rheumatoid factor or anticitrullinated protein antibodies) and X-rays help distinguish RA/SCD.




Other autoimmune diseases and SCD

- Prevalence of **autoimmune liver disease (0,5%)** is **higher** than in the general population (**1/100 000**).

Allali, JCM 2019



Colli, Lancet 2018



Other autoimmune diseases and SCD

- **RBC autoantibodies** are frequent ($\approx 8\%$) in transfused patients: **risk factor for alloimmunization**.


Allali, Br J Haematol 2017

- Prevalence of type 1 and 2 **diabetes mellitus** is **lower** than in the general population.


Role of lower obesity rate in SCD patients (hypermetabolism, dysbiosis...)

Fung, Br J Haematol 2006


Zouh, Br J Haematol 2019



Autoimmune diseases in SCD children




Allali, unpublished




Learning objectives

1. How could SCD promote autoimmunity?
2. Are patients with SCD more prone to autoimmune diseases?
- 3. What are the therapeutic implications of autoimmunity in SCD?**



Main treatments of autoimmune diseases

- **Glucocorticoids** are the **most frequently used initial** anti-inflammatory drugs in autoimmune diseases.
- Many **adverse effects**: Cushing's syndrome, adrenal suppression, hyperglycemia, dyslipidemia, cardiovascular disease, osteoporosis, immunosuppression,...
- During **chronic** maintenance treatment, they **should be minimized** and, when possible, **withdrawn**.
- **Immunomodulatory agents** and **biological therapies** can help taper/discontinue glucocorticoids.





Glucocorticoids and SCD

- Increased risk of **VOC** and **ACS** with **glucocorticoids** in SCD, due to **leukocyte demargination**

Walter, Blood 2022

Allali, Haematologica 2020





Glucocorticoids and autoimmune diseases in SCD

- Increased incidence of **VOC** and **ACS** during **autoimmune diseases treated with glucocorticoids**.


Michel, Semin Arthritis Rheum 2008

Li-Thiao-Te, Pediatr Rheumatol Online J 2018

- **Transfusions/Exchange transfusions** are often required with glucocorticoids.

Li-Thiao-Te, Pediatr Rheumatol Online J 2018

Allali, JCM 2019



Other therapies for autoimmune diseases in SCD

- **Immunomodulators** and **biologics** (e.g. anti-TNF- α antibodies) are at **increased risk of infection**


(azathioprine, methotrexate,...)

(infliximab, adalimumab,...)



Importance of **vaccination** and immediate **consultation** in case of signs of infection (fever,...)

- **Methotrexate** and other disease-modifying antirheumatic drugs are at **increased risk of cytopenia**
- **Excellent tolerance** of these therapies **overall**



Treatments of SCD and autoimmune diseases

- **Hydroxyurea reduces autoimmunity** by decreasing innate immune cell count and antibody production.


Piccin, Br J Haematol 2022

- **Hematopoietic stem cell transplantation** can cure autoimmune diseases together with SCD.

Li-Thiao-Te, Pediatr Rheumatol Online J 2018


- **Risk of recurrence** of autoimmune hepatitis after liver transplantation **if HCST is not done.**

Allali, JCM 2019



Take-home message

1. **Increased risk** of autoimmune diseases in SCD
2. **Glucocorticoids** should not be used without concomitant **transfusions**
3. **Hydroxyurea** reduces the risk and **HSCT** can cure autoimmune diseases



Discussion